Rosacea News and Research

Latest Rosacea News and Research

Proper skin care, cosmetics can improve skin of acne and rosacea patients

Patients with acne and rosacea are often confused about selecting appropriate skin care products, cosmeceuticals and cosmetics to add into their daily routine. While they want to continue to see results with the treatment regimen from their dermatologist, they also want to be comfortable using products that address other skin issues, such as wrinkles or that protect their skin, such as sunscreens.

5 Feb 2011

Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea

Vicept Therapeutics, Inc. announced positive study results from a Phase II clinical trial evaluating the dose-response relationship of four concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea (Erythematotelangiectatic Rosacea). The results demonstrated a statistically significantrebound" or tachyphylaxis was observed.

10 Jan 2011

KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced the initiation of two European Phase III studies evaluating ATX-101, a first-in-class injectable adipolytic agent, for the reduction of localized fat under the chin (submental fat).

10 Jan 2011

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, and Galderma, a global leading pharmaceutical company dedicated exclusively to the field of dermatology, announce the expansion of their multi-year collaboration agreement. Based on positive data assessing the activity of NovaBay's Aganocide compounds against impetigo, Galderma has agreed to exercise its option for this indication.

6 Dec 2010

Obagi Medical Products prices secondary offering

Obagi Medical Products, Inc., a leader in topical aesthetic and therapeutic skin health systems, today announced the pricing of the secondary public offering of 2,690,244 shares of its common stock by the Stonington Capital Appreciation 1994 Fund, L.P. and the Zein and Samar Obagi Family Trust, at a public offering price of $10.25 per share.

20 Nov 2010

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced results of two Phase III studies of its patented Carbamide Peroxide (CPO) solution for the treatment of inflammatory acne vulgaris and rosacea at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.

19 Nov 2010

NIAMS awards $684,000 SBIR grant to Signum Biosciences to develop GPCR modulating therapeutics

Signum Biosciences, Inc. was recently awarded two Small Business Innovation Research (SBIR) Phase I grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the NIH, totaling over $684,000 for development of novel G-protein coupled receptor (GPCR) modulating therapeutics designed to treat common skin disorders.

20 Sep 2010

Quick-Med receives patent for MultiStat technology to treat Rosacea

15 Sep 2010

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

31 Aug 2010

V-101 shows safety profile in treating erythema of rosacea: Clinical study

Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced positive results from a pharmacodynamic and pharmacokinetic clinical trial of the Company's lead product V-101, a topical cream under investigation for the treatment of erythema in patients with rosacea.

6 Aug 2010

Price of sun overindulgence and tanning misuse is not just skin deep

It's what marketers lead us to believe is the picture of glowing health - the ultimate tan. But sun overindulgence and tanning misuse does have a price. And it's not just skin deep.

28 Jul 2010

JDD publishes long-term efficacy and tolerability study of PyratineXR Moisturizing Lotion

The June 2010 issue of Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication serving the dermatology community, features a study on the long-term efficacy and tolerability of the active ingredient in PyratineXR™.

16 Jul 2010

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan. Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs).

12 Jul 2010

Vicept completes $16 million Series A financing

Vicept™ Therapeutics Inc., a privately held specialty biopharmaceutical company dedicated to developing the first effective topically applied therapy for erythema (facial redness) of rosacea, announced that it has secured $10 million to complete a total $16 million Series A financing. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences.

30 Jun 2010

Quick-Med Technologies receives Notice of Allowance for MultiStat family of compounds

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that extends the current patent coverage for the Company's MultiStat family of compounds. The forthcoming patent is part of a portfolio that Quick-Med has licensed from the University of Michigan.

18 Jun 2010

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $270,000 to Signum Biosciences, Inc. (Princeton, NJ) to evaluate small-molecule, orally delivered Protein Phosphatase 2a (PP2A)-modulatory compounds as disease-modifying therapeutics for Alzheimer's disease.

1 Apr 2010

Helix BioMedix reports revenue of approximately $391,000 in 2009

Helix BioMedix, Inc., a developer of bioactive peptides, announced financial results for the year ended December 31, 2009.

26 Mar 2010

Galderma Laboratories' Differin Lotion receives FDA approval

Galderma Laboratories, L.P. today announced the U.S. Food and Drug Administration approval of Differin® (adapalene) Lotion, 0.1%, the first-ever lotion formulation of the well-tolerated retinoid adapalene, for the treatment of acne. Differin Lotion, 0.1% will be available by prescription in April 2010.

22 Mar 2010

Proper diagnosis, treatment and good skin care help control acne and rosacea

Acne and rosacea are two seemingly different skin conditions that have one important thing in common: both are chronic and extremely common skin conditions. However, dermatologists recommend that with proper diagnosis, treatment and a healthy dose of good, old-fashioned skin care, acne and rosacea can be less of a nuisance for patients.

5 Mar 2010

freshHAIR: A new hair care line to prevent acne

Renee Cobos, MD, a board certified dermatologist and associate professor of dermatology at the University of California, Irvine, announced the launch of RC freshHAIR™, the first dermatologist-created hair care line that is specifically formulated to treat and prevent acne, acne rosacea, seborrhea (dandruff) and oily skin. RC freshHAIR is the newest addition to the RC Dermatology™ line of skin care products.

18 Jan 2010

Rosacea News and Research

Latest Rosacea News and Research

Proper skin care, cosmetics can improve skin of acne and rosacea patients

Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea

KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

Obagi Medical Products prices secondary offering

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

NIAMS awards $684,000 SBIR grant to Signum Biosciences to develop GPCR modulating therapeutics

Quick-Med receives patent for MultiStat technology to treat Rosacea

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

V-101 shows safety profile in treating erythema of rosacea: Clinical study

Price of sun overindulgence and tanning misuse is not just skin deep

JDD publishes long-term efficacy and tolerability study of PyratineXR Moisturizing Lotion

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Vicept completes $16 million Series A financing

Quick-Med Technologies receives Notice of Allowance for MultiStat family of compounds

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

Helix BioMedix reports revenue of approximately $391,000 in 2009

Galderma Laboratories' Differin Lotion receives FDA approval

Proper diagnosis, treatment and good skin care help control acne and rosacea

freshHAIR: A new hair care line to prevent acne

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Rosacea News and Research

Latest Rosacea News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in